PCVX
Vaxcyte·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PCVX
Vaxcyte, Inc.
A clinical-stage vaccine innovation company that engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases
825 Industrial Road, Suite 300, San Carlos, California 94070
--
Vaxcyte, Inc., was incorporated in Delaware on November 27, 2013. The company is a next-generation vaccine company that aims to improve global health by developing novel vaccines to prevent or treat some of the world's most common and deadly infectious diseases. Their cell-free protein synthesis platform enables them to design and produce protein carriers and antigens, which are key components of vaccines.
Company Financials
EPS
PCVX has released its 2025 Q3 earnings. EPS was reported at -1.56, versus the expected -1.25, missing expectations. The chart below visualizes how PCVX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
